Press Releases Axsome Therapeutics, Inc.

Equities

AXSM

US05464T1043

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
73.69 ^USD	+2.76%		+3.64%	-7.41%

Apr. 29	Axsome Therapeutics Phase 3 Alzheimer's Treatment Trial is High Risk, High Reward, Morgan Stanley Says	MT
Apr. 29	Morgan Stanley Upgrades Axsome Therapeutics to Overweight From Equalweight, Raises Price Target to $115 From $90	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Axsome Therapeutics highlights innovative neuroscience portfolio at the american academy of neurology 2024 annual meeting	Apr. 16	AQ
Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting	Apr. 15	GL
Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting	Apr. 15	AQ
Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6	Apr. 10	GL
Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder	Apr. 01	GL
Axsome Therapeutics : AXS-12 SYMPHONY Results - Slides	Mar. 25	PU
Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients	Mar. 25	GL
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy	Mar. 25	GL
Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder	Mar. 19	GL
Axsome Therapeutics to Present at the Leerink Partners Global Biopharma Conference	Mar. 05	GL
Axsome Therapeutics to Present at the Leerink Partners Global Biopharma Conference	Mar. 05	AQ
Axsome Therapeutics to Present at the TD Cowen 44th Annual Healthcare Conference	Feb. 27	GL
Enpro, Axsome Therapeutics fall; Walmart, Medtronic rise, Tuesday, 2/20/2024	Feb. 20	AQ
Axsome: Q4 Earnings Snapshot	Feb. 20	AQ
Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	Feb. 20	GL
Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	Feb. 20	AQ
Axsome Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 20	Jan. 23	GL
Southern District Of New York Dismisses Proposed Securities Class Action Complaint Against Drug Manufacturer For Failure To Plead Loss Causation	Jan. 17	AQ
Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones	Jan. 04	AQ
Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones	Jan. 04	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Axsome Therapeutics, Inc.

Equities

AXSM

US05464T1043

Press Releases

Filters